Article Text

other Versions

Download PDFPDF
Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU
  1. Pierre Voirol1,2,
  2. Markoulina Berger-Gryllaki1,
  3. André Pannatier1,2,
  4. Philippe Eggimann3,
  5. Farshid Sadeghipour1,2
  1. 1Service of Pharmacy, Lausanne University Hospital (CHUV), Lausanne, Switzerland
  2. 2School of Pharmaceutical Sciences, University of Geneva and University of Lausanne, Geneva, Switzerland
  3. 3Service of Intensive Care Medicine, Lausanne University Hospital (CHUV), Lausanne, Switzerland
  1. Correspondence to Dr Pierre Voirol, Service of Pharmacy, Lausanne University Hospital (CHUV), 46, Rue du Bugnon, Lausanne 1011, Switzerland; pierre.voirol{at}


Objective Insulin as continuous infusion is frequently used in critical care. Data on compatibilities are available for regular insulin but not for insulin aspart. The present study aimed at assessing the physical compatibility of insulin aspart with 47 drugs commonly used in intensive care units by simulated Y-site administration.

Methods The physical compatibility of insulin aspart 1 IU/mL in sodium chloride 0.9% and in dextrose 5% was evaluated by visual inspection over a 24 h period. Tested drugs were diluted in the same solvents or tested without dilution, based on standard practices. Tests were conducted in duplicates.

Results Insulin aspart was compatible over 24 h with 43 drugs over the 47 selected. Imipenem-cilastin, meropenem, esomeprazole and pantoprazole were compatible over a shorter period.

Conclusions Of the 47 drugs tested, only four were not physically compatible over 24 h. Our data will allow a switch from regular insulin to insulin aspart if needed.

  • Intensive & Critical Care
  • Stability And Incompatibility
  • Drug analysis < Laboratory / Quality Control

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.